Tyra Biosciences, Inc. TYRA
Regular-session close
After hours · Nov 19, 5:26 PM ET
- YTD
- -24.95%
- 1 year
- +18.71%
- Market cap
- 1.36B
- EPS (ttm)
- -2.63
- Shares out
- 69.08M
- Forward P/E
- -6.68
- YTD return
- -24.95%
- 1-year return
- +18.71%
- 50-day average
- 21.38
- 200-day average
- 29.24
- Enterprise value
- 659.63M
- Price / book
- 1.96
- Volume
- 346.57K
- Avg volume
- 852.62K
- Open
- 19.63
- Previous close
- 19.61
- Day's range
- 19.26 – 20.18
- 52-week range
- 16.86 – 40.65
- Beta
- 0.67
- Analysts
- Strong Buy
- Price target
- 47.45 (+140.5%)
- Earnings date
- Mar 1, 2027
Key statistics
- Free cash flow
- -66.89M
- Total cash
- 700.55M
- Total debt
- 5.46M
- Return on equity
- -34.89%
- Short % of float
- 23.75%
Fundamental scorecard
4 of 25 checks passed on TYRA’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 27.00
- Target (mean)
- 47.45
- Target (high)
- 59.00
- Strong buy2
- Buy12
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate -0.665.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | -0.71 | — | — | — |
| Nov 10, 2026 | Sep 30, 2026 | -0.66867 | -0.74 | -0.07 | -10.67% |
| Aug 4, 2026 | Jun 30, 2026 | -0.64989 | -0.69 | -0.04 | -6.17% |
| May 13, 2026 | Mar 31, 2026 | -0.60 | -0.64 | -0.04 | -6.67% |
| Mar 2, 2026 | Dec 31, 2025 | -0.54 | -0.57 | -0.03 | -5.56% |
| Nov 5, 2025 | Sep 30, 2025 | -0.50 | -0.50 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | Wedbush | main | Outperform | Outperform |
| Nov 11, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 22, 2026 | Oppenheimer | reit | Outperform | Outperform |
| Sep 22, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 10, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 10, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tyra.bio
News
Nvidia To $200? Here Are 10 Top Analyst Forecasts For Wednesday Wedbush Maintains Outperform on Tyra Biosciences, Raises Price Target to $57
HC Wainwright & Co. Maintains Buy on Tyra Biosciences, Lowers Price Target to $27
Tyra Biosciences Q3 EPS $(0.74) Misses $(0.69) Estimate
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Your note
Sign in to keep a note on TYRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASHAR BHAVESH | Chief Operating Officer | Stock Award(Grant) | May 4, 2026 | 15,013 |
| BENSEN DANIEL | Officer | Sale | Feb 11, 2026 | 146,981 |
| FUHRMAN ALAN CPA | Chief Financial Officer | Stock Award(Grant) | May 4, 2026 | 36,164 |
| HARRIS TODD JAMES | Chief Executive Officer | Stock Award(Grant) | May 4, 2026 | 1,437,630 |
| KAPLAN GILLA | Director | Conversion of Exercise of derivative security | Mar 25, 2026 | 28,231 |
| KJELLSON NINA S | Director | Sale | Feb 4, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 17.66% | 12,198,625 | 240.68M | Sep 29, 2026 |
| FMR, LLC | 15.25% | 10,538,463 | 207.92M | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 7.62% | 5,261,720 | 103.81M | Sep 29, 2026 |
| BVF Inc. | 6.10% | 4,215,886 | 83.18M | Sep 29, 2026 |
| Alta Partners Management Company, L.P. | 5.53% | 3,823,425 | 75.44M | Sep 29, 2026 |
| Paradigm Biocapital Advisors LP | 5.08% | 3,510,360 | 69.26M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Securities Fund-Fidelity OTC Portfolio | 4.80% | 3,317,036 | 65.45M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.67% | 1,154,855 | 22.79M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.64% | 1,135,472 | 22.40M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.38% | 956,773 | 18.88M | Sep 29, 2026 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 1.26% | 871,831 | 17.20M | Oct 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 1.15% | 793,140 | 15.65M | Jun 29, 2026 |
